2-diethylaminopyrazine | 65032-09-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-diethylaminopyrazine
• 英文别名: Diaethylaminopyrazin；diethyl-pyrazin-2-yl-amine；N,N-diethylpyrazin-2-amine
• CAS: 65032-09-9
• 化学式: C₈H₁₃N₃
• mdl: MFCD15144374
• 分子量: 151.211
• InChiKey: JVWSLVXOJTWOET-UHFFFAOYSA-N

物化性质

• 沸点：
  232.3±20.0 °C(Predicted)
• 密度：
  1.029±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-diethylaminopyrazine 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 二甲基亚砜 为溶剂， 生成 3,5-Dibromo-N,N-diethylpyrazin-2-amine
  参考文献：
  名称：

  2,3-Diaminopyrazines as rho kinase inhibitors

  摘要：

  Inhibition of rho kinase ( ROCK) has been recognized as an important target for a number of diseases, including glaucoma. Herein we report SAR development around two hits from a kinase library that led to the discovery of the ROCK inhibitor compound 38. In vitro and in vivo analysis of this compound, including its effects in a monkey model of glaucoma will be discussed. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.012
• 作为产物：
  描述：

  2-氯吡嗪 、 二乙胺 以 二甲基亚砜 为溶剂， 生成 2-diethylaminopyrazine
  参考文献：
  名称：

  2,3-Diaminopyrazines as rho kinase inhibitors

  摘要：

  Inhibition of rho kinase ( ROCK) has been recognized as an important target for a number of diseases, including glaucoma. Herein we report SAR development around two hits from a kinase library that led to the discovery of the ROCK inhibitor compound 38. In vitro and in vivo analysis of this compound, including its effects in a monkey model of glaucoma will be discussed. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.12.012

文献信息

• Acyclic tertiary amines as nucleophiles in substitution reactions of aromatic and heteroaromatic halides
  作者：Kiyoshi Matsumoto、Shiro Hashimoto、Shinichi Otani

  DOI：10.1039/c39910000306

  日期：——

  Even acyclic tertiary amines such as triethylamine, tri-n-propylamine and tri-n-butylamine, which have been believed to be inert to aromatic and heteroaromatic halides, underwent SNAr reactions with aromatic and heteroaromatic halides to give the dialkylamino derivatives; in the case of monocyclic amines like N-methylpyrrolidine and N-methylpiperidine, the dealkylation being regioselective.

  甚至被认为对芳族和杂芳族卤化物呈惰性的无环叔胺，如三乙胺，三正丙胺和三正丁胺，也与芳族和杂芳族卤化物进行S N Ar反应，得​​到二烷基氨基衍生物；在单环的胺等的情况下Ñ -甲基吡咯烷和Ñ甲基哌啶，脱烷基化区域选择性被。
• Studies on Pyrazines; 21.¹A Convenient Synthesis of Pyrazinecarboxylic Acid Derivatives from Chloropyrazines
  作者：Ryo Takeuchi、Katsunobu Suzuki、Nobuhiro Sato

  DOI：10.1055/s-1990-27055

  日期：——

  Palladium-catalyzed carbonylation of chloropyrazines in methanol led to pyrazinecarboxylic esters in good yields. Similarly, pyrazinecarboxamides were obtained by using dialkylamines or alkylamines as the solvent.

  在甲醇中，以钯催化的氯吡嗪羰基化反应生成了产量良好的吡嗪羧酸酯。同样，使用二烷基胺或烷基胺作为溶剂也成功获得了吡嗪羧酸胺。
• [EN] RIPK1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE RIPK1 ET PROCÉDÉS D'UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2021252307A1

  公开（公告）日：2021-12-16

  Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.

  本文描述的是化合物的结构式（I）或其药用可接受的盐。式（I）化合物作为RIPK1抑制剂，可用于预防、治疗或作为RIPK1相关疾病的治疗剂。
• 7-Substituted bicyclic pyrazolidinones
  申请人：ELI LILLY AND COMPANY

  公开号：EP0202046A1

  公开（公告）日：1986-11-20

  7-Substituted bicyclic pyrazolidinone compounds as antimicrobials and the corresponding intermediates, are discussed or provided. The use of the antimicrobial compounds in pharmaceutical compositions and in methods for treating bacterial infections is set forth. The pyrazolidinone compounds are of the formula wherein one of R1 and R2 is hydrogen, halo, C1 to C6 alkyl, C1 to C6 substituted alkyl, perfluoro C2 to C4 alkyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl, phenyl, substituted phenyl, a heterocyclic ring, nitro or cyano; a group of the formula wherein X is fluoro, chloro, bromo or iodo; a group of the formula wherein z is 0, 1 or 2 and R7 is C1 to C6 alkyl, C1 to C6 substituted alkyl, phenyl, substituted phenyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl or a heterocyclic ring; a group of the formula wherein R8 is hydrogen, C1 to C6 alkyl, C, to C6 substituted alkyl, perfluoro C2 to C4 alkyl, trihalomethyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl, phenyl, substituted phenyl, amino, (monosubstituted)amino, or (disubstituted)amino; a group of the formula wherein R9 is hydrogen, an organic or inorganic cation, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl, phenyl, substituted phenyl, a carboxy-protecting group, or a non-toxic, metabolically-labile, ester-forming group; a group of the formula wherein R10 is hydrogen, an organic or inorganic cation, C1 to C5 alkyl, C, to G6 aubatituted allcyl, C7 to C12 arylalkyl, C7 to C12 aubatltuted arylalkyl, phenyl, or substituted phenyl; a group of the formula ⊕ wherein -N≡Q is a quaternary ammonium group; or a group of the formula -CH2-S-Heterocycllc ring; a group of the formula wherein R11 is hydrogen, C1 to Ce alkyl, C, to Ce substituted alkyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl, phenyl, substituted phenyl or C1 to C7 acyl; or a group of the formula wherein R12 and R13 are the same or different and are hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl, phenyl, substituted phenyl, C1 to C7 acyl, or a group of the formula; wherein Rq is C, to C6 alkyl, C7 to C12 arylalkyl or phenyl; and the other of R, and R2 is a group of the formula wherein R14 is hydrogen, an organic or inorganic cation, a carboxy-protecting group or a non-toxic, metabolically-labile ester-forming group; and R3 and R4 are the same or different and are hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 arylalkyl, C7 to C12 substituted arylalkyl, phenyl, substituted phenyl or a group of the formula wherein R15 has the same definition as R9; R5 and R6 are: 1) each hydrogen, an amino protecting group; or acyl group derived from a C, to C30 carboxylic acid; provided that at least one of Rs and R6 must be hydrogen; or 2) taken together to form a phthalimido group; or a pharmaceutically-acceptable salt thereof.

  讨论或提供了作为抗菌剂的 7-取代双环吡唑烷酮化合物及相应的中间体。阐述了抗菌化合物在药物组合物和治疗细菌感染方法中的用途。吡唑烷酮化合物的结构式如下 其中 R1 和 R2 之一为氢、卤素、C1 至 C6 烷基、C1 至 C6 取代烷基、全氟 C2 至 C4 烷基、C7 至 C12 芳烷基、C7 至 C12 取代芳烷基、苯基、取代苯基、杂环、硝基或氰基； 式中的基团 其中 X 是氟、氯、溴或碘； 式中的基团 其中 z 是 0、1 或 2，R7 是 C1 至 C6 烷基、C1 至 C6 取代的烷基、苯基、取代的苯基、C7 至 C12 芳烷基、C7 至 C12 取代的芳烷基或杂环； 式中的基团 其中 R8 是氢、C1 至 C6 烷基、C, 至 C6 取代的烷基、全氟 C2 至 C4 烷基、三卤甲基、C7 至 C12 芳烷基、C7 至 C12 取代的芳烷基、苯基、取代的苯基、氨基、(单取代)氨基或(二取代)氨基； 式中的基团 其中 R9 是氢、有机或无机阳离子、C1～C6 烷基、C1～C6 取代的烷基、C7～C12 芳烷基、C7～C12 取代的芳烷基、苯基、取代的苯基、羧基保护基团或无毒、代谢上易腐烂的酯形成基团； 式中的基团 其中 R10 是氢、有机或无机阳离子、C1 至 C5 烷基、C, 至 G6 亚氨基全烷基、C7 至 C12 芳烷基、C7 至 C12 亚氨基芳烷基、苯基或取代苯基； 式中的基团 ⊕ 其中-N≡Q 是季铵基团；或式中-CH2-S-杂环的基团； 式中的基团 其中 R11 是氢、C1 至 Ce 烷基、C1 至 Ce 取代的烷基、C7 至 C12 芳烷基、C7 至 C12 取代的芳烷基、苯基、取代的苯基或 C1 至 C7酰基；或式中的基团 其中 R12 和 R13 相同或不同，并且是氢、C1 至 C6 烷基、C1 至 C6 取代的烷基、C7 至 C12 芳烷基、C7 至 C12 取代的芳烷基、苯基、取代的苯基、C1 至 C7酰基或式中的基团； 其中 Rq 是 C 至 C6 烷基、C7 至 C12 芳烷基或苯基；以及 R 和 R2 中的另一个是式中的基团 其中 R14 是氢、有机或无机阳离子、羧基保护基团或无毒、可代谢的成酯基团； R3 和 R4 相同或不同，并且是氢、C1 至 C6 烷基、C1 至 C6 取代的烷基、C7 至 C12 芳烷基、C7 至 C12 取代的芳烷基、苯基、取代的苯基或式中的一个基团。 其中 R15 的定义与 R9 相同； R5 和 R6 为 1) 各为氢、氨基保护基；或由 C 至 C30 羧酸衍生的酰基； 但 Rs 和 R6 中至少有一个必须是氢；或 2) 结合在一起形成邻苯二甲酰亚胺基团；或其药学上可接受的盐。
• Bicyclic pyrazolidinones
  申请人：ELI LILLY AND COMPANY

  公开号：EP0203722A1

  公开（公告）日：1986-12-03

  Bicyclic pyrazolidinones which have antimicrobial and/or herbicidal properties are discussed. The use of these compounds in pharmaceutical compositions, herbicidal compositions, and methods for treating bacterial infections and controlling undesired plants is set forth. The bicyclic pyrazolidinones have the formula wherein: either R1 or R2 is hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, perfluoro C2 to C4 alkyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl, phenyl, substituted phenyl, nitro br cyano; a group of the formula wherein X is fluoro, chloro, bromo or iodo; a group of the formula wherein Z is 0, 1 or 2 and Rs is C1 to C6 alkyl, C1 to C6 substituted alkyl, phenyl, substituted phenyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl or a heterocyclic ring; a group of the formula wherein R6 is hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, perfluoro C2 to C4 alkyl, trihalomethyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl, phenyl or substituted phenyl; a group of the formula wherein R7 is hydrogen, an organic or inorganic cation, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl, phenyl, substituted phenyl, a carboxy protecting group, or a non-toxic, metabolically-labile ester-forming group; or a group of the formula wherein R8 is hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 substituted alkylaryl, phenyl, or substituted phenyl; a group of the formula wherein -N≡Q is a quaternary ammonium group; or a group of the formula -CH2-S-Heterocyclic-ring and the other of R1 or R2 is a group of the formula wherein R9 is hydrogen, an organic or inorganic cation, a carboxy protecting group, or a non-toxic, metabolically-labile ester-forming group; and R3 and R4 are the same or different and are hydrogen, C1 to C6 alkyl, C1 to C6 substituted alkyl, C7 to C12 alkylaryl, C7 to C12 substituted alkylaryl, phenyl, substituted phenyl or a group of the formula wherein R10 has the same definition as R7; with the exception that, when R1 and R2 are a group of the formula R3 and R4 are not methyl; or a pharmaceutically-acceptable salt thereof.

  本文讨论了具有抗菌和/或除草特性的双环吡唑烷酮。阐述了这些化合物在药物组合物、除草组合物中的用途，以及治疗细菌感染和控制有害植物的方法。双环吡唑烷酮的化学式为 其中 R1 或 R2 是氢、C1 至 C6 烷基、C1 至 C6 取代烷基、全氟 C2 至 C4 烷基、C7 至 C12 烷芳基、C7 至 C12 取代烷芳基、苯基、取代苯基、硝基溴氰基； 式中的基团 其中 X 为氟、氯、溴或碘； 式中的基团 其中 Z 是 0、1 或 2，Rs 是 C1 至 C6 烷基、C1 至 C6 取代的烷基、苯基、取代的苯基、C7 至 C12 烷芳基、C7 至 C12 取代的烷芳基或杂环； 式中的基团 其中 R6 是氢、C1 至 C6 烷基、C1 至 C6 取代的烷基、全氟 C2 至 C4 烷基、三卤甲基、C7 至 C12 烷芳基、C7 至 C12 取代的烷芳基、苯基或取代的苯基； 式中的基团 其中 R7 是氢、有机或无机阳离子、C1-C6 烷基、C1-C6 取代烷基、C7-C12 烷芳基、C7-C12 取代烷芳基、苯基、取代苯基、羧基保护基团或无毒、代谢上易形成酯的基团； 或一个式中的基团 其中 R8 是氢、C1 至 C6 烷基、C1 至 C6 取代的烷基、C7 至 C12 取代的烷芳基、苯基或取代的苯基； 式中的基团 其中 -N≡Q 是季铵基团； 或式中的基团 -CH2-S-杂环，而 R1 或 R2 中的另一个是式中的基团 其中 R9 是氢、有机或无机阳离子、羧基保护基团或无毒、可代谢的成酯基团；以及 R3 和 R4 相同或不同，并且是氢、C1 至 C6 烷基、C1 至 C6 取代的烷基、C7 至 C12 烷芳基、C7 至 C12 取代的烷芳基、苯基、取代的苯基或式中的基团 其中 R10 的定义与 R7 相同；但当 R1 和 R2 为式中的基团时 R3 和 R4 不是甲基；或其药学上可接受的盐。